🎙️Tune in to Episode 194 of #TheGeneticsPodcast 🚀 This week, we’re joined by Melissa Haendel, Director of Translational Informatics and Precision Health and Professor at the University of North Carolina at Chapel Hill, and Phenotypic Lead at Alamya Health. Listen in to hear

🧬 Ocugen’s one-time gene therapy, OCU400ST, just advanced to a pivotal trial. Dr. Huma Qamar, CMO at Ocugen, joined The Genetics Podcast to share what this means for kids with Stargardt disease — a rare cause of early blindness with no approved treatments. #GeneTherapy

AI is rebuilding the clinical trial stack and engineers are leading the charge. ✅ Automate eligibility 🧬 Analyze genomics at scale ⚙️ Rethink trial setup from the ground up Smarter trials start with smarter systems. Read for examples from Sano & more: eu1.hubs.ly/H0lwqVs0

We recently attended the GBA1 conference in Montreal and gained deep insight into the challenges and opportunities in this field. In this blog, we explore why precision medicine is essential but still out of reach for many, and how better trial design, patient inclusion, and

On a recent episode of The Genetics Podcast, we talked to Andres Moreno-Estrada about the creation of the Mexican Biobank, uncovering hidden ancestry, ancient migration, and why local leadership in genomics matters. Read the recap: eu1.hubs.ly/H0lzPrh0 #TheGeneticsPodcast

Traditional randomized controlled trials aren’t built for the era of precision medicine, especially when working with small, genetically-defined populations. In our new whitepaper, we explore how smarter designs can make trials more flexible, patient-centered, and efficient.

AI is changing how we design clinical trials, but it’s not just about speed. It’s about smarter workflows, better tools, and thoughtful integration. 💬 In this conversation, William Jones, CTO of Sano, shares practical lessons from embedding AI into trial setup, team culture,

🎙️Tune in to Episode 195 of #TheGeneticsPodcast 🚀 This week, we’re joined by David Bumcrot, Chief Scientific Officer of CAMP4 Therapeutics. Listen in to hear about David’s involvement in the development of the breakthrough technologies in RNA interference and CRISPR, how

🧬 How do you design gene therapies that work for 100+ mutations at once? In a recent episode of The Genetics Podcast, Dr. Huma Qamar of Ocugen explains how their gene-agnostic platform could transform care for patients with rare retinal diseases, many of whom have no treatment

Autophagy is gaining traction as a therapeutic target in neurodegeneration and rare disease. In a recent episode of The Genetics Podcast, Frank Gentile, CEO of Casma Therapeutics, discussed how TRPML1 and lysosomal repair could change the treatment landscape for Parkinson’s

Traditional clinical trials are too slow, too expensive, and often fail to reflect real-world populations. Our latest whitepaper explores how AI and real-world data are making trials faster, smarter, and more inclusive, from cleaning messy data to building synthetic control arms.

What if rare disease data were treated like public utilities? On a recent episode of The Genetics Podcast, Melissa Haendel shared how unified disease ontologies (like Mondo), patient input, and community-based genomics could transform rare disease diagnosis and equity. Read the

In the latest episode of The Genetics Podcast, we spoke with Dr. David Bumcrot, CSO at CAMP4 Therapeutics, about how non-coding RNAs that were once thought to be junk are now unlocking a new therapeutic modality. The blog recap covers his lessons from pioneering RNAi and CRISPR,

🎙️Tune in to Episode 196 of #TheGeneticsPodcast 🚀 This week, we’re joined by Molly He, CEO and co-founder of Element Biosciences. Listen in to hear about the current landscape of sequencing technologies, the advantages and technical overview of Element Biosciences's powerful sequencing

What does a week in the life of a bioinformatician at Sano look like? Jonny Talbot-Martin is on a mission to unify pipelines that scale and adapt, apply scientific rigor to every data decision, and bridge biology with engineering to deliver results with confidence. Go behind

In the latest episode of The Genetics Podcast, Dr. Molly He, CEO of Element Biosciences, joins us to talk about sequencing innovation and the power of integrated multi-omics.🧬 We’ve recapped the conversation, including how Element’s platform is enabling richer biological

At the FDA’s recent roundtable on cell and gene therapy, panelists called for major shifts in how trials are designed and run. They highlighted the need for streamlined regulatory pathways for bespoke therapies, clearer regulatory feedback, and stronger incentivization for drug

🎙️Tune in to Episode 197 of #TheGeneticsPodcast 🚀 This week, we’re joined by Heiko Runz, medical geneticist and VP of Neuroscience at insitro . Listen in to hear about Heiko Runz's path from academia to industry, his role in developing tofersen for SOD1 ALS, how he integrates

🎙️ In the latest episode of The Genetics Podcast, we speak with Dr. Heiko Runz, SVP of Neuroscience at insitro, about how population-scale genomics and AI are transforming drug discovery. He shares insights on biobank-powered target discovery, the importance of functional